7 November 2024
Roquefort Therapeutics
plc
("Roquefort Therapeutics" or the "Company")
Conversion of Convertible
Loan Notes
Roquefort Therapeutics
(LSE:ROQ), the Main Market listed biotech
company focused on developing first in
class medicines in the high value and high growth immunology and
oncology markets, announces it has received
notices to convert a total face value of £267,106 convertible loan
notes (the "CLNs") resulting in the issue of 6,586,604 new ordinary
shares in the Company (the "CLN Shares").
In accordance with the terms of the
CLNs, which were issued on 23 May 2024, all accrued interest on the
CLNs at a rate of 12.5% per annum is included in the conversion
into the Company's ordinary shares of £0.01 each ("Ordinary
Shares"). The conversion price of the CLNs is 4.29p, being 90% of
the price equal to the 10-day volume-weighted average price
calculated backwards from the date, which is three business days
prior to the notice of conversion given to the Company.
Following conversion of these CLNs,
the Company has CLNs with a face value of £387,894
outstanding.
Director/PDMR Shareholding
The abovementioned notices to
convert included notices from directors Stephen West, Ajan Reginald
and Darrin Disley, as follows:
|
Director
|
CLN Face
Value
|
CLN Shares
|
Total Ordinary Shares Held
After CLN Shares Issued
|
|
Stephen West
|
£28,158
|
694,352
|
6,310,853
|
|
Ajan Reginald
|
£26,316
|
648,930
|
12,311,981
|
|
Darrin Disley
|
£21,053
|
519,149
|
2,015,050
|
Admission and Total Voting Rights
Application will be made for the CLN
Shares to be admitted to trading on the London Stock Exchange's
Main Market for listed securities, which is expected to occur on or
around 12 November 2024 ("Admission"). The CLN Shares will rank
pari passu in all respects
with the Company's existing Ordinary Shares.
Following Admission, the Company's
issued share capital will comprise 135,736,602 Ordinary Shares in
issue, with each share carrying the right to one vote. The Company
does not hold any Ordinary Shares in treasury. The figure of
135,736,602 Ordinary Shares may be used by shareholders as the
denominator for the calculations by which they will determine if
they are required to notify their interest in, or of a change to
their interest in the Company under the FCA's Disclosure and
Transparency Rules.
Regulatory Information
This Announcement contains inside
information for the purposes of the UK version of the market abuse
regulation (EU No. 596/2014) as it forms part of United Kingdom
domestic law by virtue of the European Union (Withdrawal) Act 2018
("UK MAR").
ENDS
Enquiries:
|
Roquefort Therapeutics plc
|
+44 (0)20
3918 8633
|
|
Stephen West (Chairman) / Ajan
Reginald (CEO)
|
|
|
SP
Angel Corporate Finance LLP (Broker)
David Hignell / Vadim Alexandre /
Devik Mehta
|
+44 (0) 20
3470 0470
|
|
Buchanan (Public Relations)
Ben Romney / Jamie Hooper / George
Beale
|
+44 (0)20
7466 5000
|
|
Peak
IR (Investor Relations)
Seb Wykeham
|
+33 (0)7
44 44 15 42
|
LEI: 254900P4SISIWOR9RH34
About Roquefort
Therapeutics
Roquefort Therapeutics (LSE:ROQ) is
a Main Market listed biotech company developing first in class
drugs in the high value and high growth immunology and oncology markets prior
to partnering with big pharma.
Roquefort Therapeutics' portfolio
consists of five novel patent-protected pre-clinical anti-cancer
medicines. The highly complementary profile of five
best-in-class medicines consists of:
·
Midkine antibodies with
significant in
vivo efficacy and toxicology studies;
·
Midkine RNA therapeutics with novel anti-cancer
gene editing action;
·
Midkine mRNA therapeutics with novel anti-cancer
approach;
·
STAT-6 siRNA therapeutics targeting solid tumours
with significant in
vivo efficacy; and
·
MK cell therapy with direct and NK cell-mediated
anti-cancer action
For further information on Roquefort
Therapeutics, please visit www.roquefortplc.com and @RoquefortTherap on
X (formerly Twitter).
The
notification below, made in accordance with the requirements of the
UK MAR, provides further detail:
NOTIFICATION AND PUBLIC DISCLOSURE
OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES
AND PERSONS CLOSELY ASSOCIATED WITH THEM
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Stephen West
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Executive Chairman
|
|
b)
|
Initial notification
/Amendment
|
Initial
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Roquefort Therapeutics
plc
|
|
b)
|
LEI
|
254900P4SISIWOR9RH34
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
Identification code
|
Ordinary shares of £0.01 par
value
ISIN: GB00BMDQ2T15
|
|
b)
|
Nature of the transaction
|
Conversion of loan notes into
694,352 ordinary shares
|
|
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
|
|
|
4.29 pence per share
|
694,352
|
|
d
|
Aggregated information
- Aggregated volume
- Price
|
- 694,352
- 4.29p
|
|
e)
|
Date of the transactions
|
7 November 2024
|
|
f)
|
Place of the transactions
|
London Stock Exchange (XLON); Main
Market
|
The
notification below, made in accordance with the requirements of the
UK MAR, provides further detail:
NOTIFICATION AND PUBLIC DISCLOSURE
OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES
AND PERSONS CLOSELY ASSOCIATED WITH THEM
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Ajan Reginald
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Chief Executive Officer
|
|
b)
|
Initial notification
/Amendment
|
Initial
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Roquefort Therapeutics
plc
|
|
b)
|
LEI
|
254900P4SISIWOR9RH34
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
Identification code
|
Ordinary shares of £0.01 par
value
ISIN: GB00BMDQ2T15
|
|
b)
|
Nature of the transaction
|
Conversion of loan notes into
648,930 ordinary shares
|
|
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
|
|
|
4.29 pence per share
|
648,930
|
|
d
|
Aggregated information
- Aggregated volume
- Price
|
- 648,930
- 4.29p
|
|
e)
|
Date of the transactions
|
7 November 2024
|
|
f)
|
Place of the transactions
|
London Stock Exchange (XLON); Main
Market
|
The
notification below, made in accordance with the requirements of the
UK MAR, provides further detail:
NOTIFICATION AND PUBLIC DISCLOSURE
OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES
AND PERSONS CLOSELY ASSOCIATED WITH THEM
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Dr Darrin Disley
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Non-Executive Director
|
|
b)
|
Initial notification
/Amendment
|
Initial
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Roquefort Therapeutics
plc
|
|
b)
|
LEI
|
254900P4SISIWOR9RH34
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
Identification code
|
Ordinary shares of £0.01 par
value
ISIN: GB00BMDQ2T15
|
|
b)
|
Nature of the transaction
|
Conversion of loan notes into
519,149 ordinary shares
|
|
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
|
|
|
4.29 pence per share
|
519,149
|
|
d
|
Aggregated information
- Aggregated volume
- Price
|
- 519,149
- 4.29p
|
|
e)
|
Date of the transactions
|
7 November 2024
|
|
f)
|
Place of the transactions
|
London Stock Exchange (XLON); Main
Market
|
